[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].
Based on a clinical study we assessed the cost-effectiveness of treating elderly osteoporotic women with the biphosphonate Risedronat in a Swedish environment. Costs, health effects and risk of fractures were taken from previously published sources. Health effects were measured as Quality adjusted life-years (QALYs) and life-years gained. Results were presented with and without costs of added life-years. The cost-effectiveness was investigated for two patient groups. The first group consisted of elderly osteoporotic women and the second group, which was a subgroup of the first, consisted of elderly osteoporotic women with previous vertebral fractures. The cost per gained QALY, estimated at SEK 277,209 (osteoporotic women) and SEK 16,877 (osteoporotic women with a previous vertebral fracture) respectively, were in both cases below the threshold value of 520,000 SEK, indicating that the treatment was cost-effective in both patient groups. In a sensitivity analysis the cost-effectiveness for the group of osteoporotic women with previous vertebral fractures showed to be stable for variation in the parameters while the group of osteoporotic women showed to be more sensitive for variation in some of the parameters.